[1] [1] WANG M, HERBST R S, BOSHOFF C. Toward personalized treatment approaches for non-small-cell lung cancer ［J］. Nature Medicine, 2021, 27(8): 1345-1356.

[2] [2] CAO M, CHEN W. Epidemiology of lung cancer in China ［J］. Thoracic Cancer, 2019, 10(1): 3-7.

[3] [3] SMELTZER M P, WYNES M W, LANTUEJOUL S, et al. The international association for the study of lung cancer global survey on molecular testing in lung cancer ［J］. Journal of Thoracic Oncology, 2020, 15(9): 1434-1448.

[4] [4] PASSARO A, MOK T, PETERS S, et al. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations ［J］. Journal of Thoracic Oncology, 2021, 16(5): 764-773.

[5] [5] KERR K M, BIBEAU F, THUNNISSEN E, et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe ［J］. Lung Cancer, 2021, 154: 161-175.

[6] [6] ETTINGER D S, WOOD D E, AISNER D L, et al. NCCN guidelines insights: non-small cell lung cancer, version 2. 2021: featured updates to the NCCN guidelines ［J］. Journal of the National Comprehensive Cancer Network, 2021, 19(3): 254-266.

[7] [7] NAGASAKA M, ZHU V W, LIM S M, et al. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR plus NSCLC ［J］. Journal of Thoracic Oncology, 2021, 16(5): 740-763.

[8] [8] LEONETTI A, SHARMA S, MINARI R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer ［J］. British Journal of Cancer, 2019, 121(9): 725-737.

[9] [9] LAZZARI C, GREGORC V, KARACHALIOU N, et al. Mechanisms of resistance to osimertinib ［J］. Journal of Thoracic Disease, 2020, 12(5): 2851.

[10] [10] ZHENG S, ALDAHDOOH J, SHADBAHR T, et al. DrugComb update: a more comprehensive drug sensitivity data repository and analysis portal ［J］. Nucleic Acids Research, 2021, 49(W1): W174-W184.

[11] [11] LEI H, FAN S, ZHANG H, et al. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors ［J］. European Journal of Medicinal Chemistry, 2020, 186: 111888.

[12] [12] OU S H I, CUI J, SCHROCK A B, et al. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib ［J］. Lung Cancer, 2017, 108: 228-231.

[13] [13] ZHENG D, HU M, BAI Y, et al. EGFR G796D mutation mediates resistance to osimertinib ［J］. Oncotarget, 2017, 8(30): 49671.

[14] [14] MA L, CHEN R, WANG F, et al. EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib ［J］. Annals of Translational Medicine, 2019, 7(9): 207.

[15] [15] FANG W, GAN J, HUANG Y, et al. Acquired EGFR L718V mutation and loss of T790M-mediated resistance to osimertinib in a patient with NSCLC who responded to afatinib ［J］. Journal of Thoracic Oncology, 2019, 14(12): e274-e275.

[16] [16] DUAN Q, WANG G, WANG M, et al. LncRNA RP6‐65G23. 1 accelerates proliferation and inhibits apoptosis via p‐ERK1/2/p‐AKT signaling pathway on keratinocytes ［J］. Journal of Cellular Biochemistry, 2020, 121(11): 4580-4589.

[17] [17] DING J, DING X, LENG Z. LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma ［J］. Journal of Cancer, 2022, 13(6): 1837.

[18] [18] SONG L, LI D, GU Y, et al. MicroRNA-126 targeting PIK3R2 inhibits NSCLC A549 cell proliferation, migration, and invasion by regulation of PTEN/PI3K/AKT pathway ［J］. Clinical Lung Cancer, 2016, 17(5): e65-e75.

[19] [19] WU C, YANG J, LI R, et al. LncRNA WT1-AS/miR-494-3p regulates cell proliferation, apoptosis, migration and invasion via PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer ［J］. OncoTargets and Therapy, 2021, 14: 891-904.

[20] [20] LIU X X, YANG Y E, LIU X, et al. A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma ［J］. Journal of Translational Medicine, 2019, 17(1): 50.

[21] [21] CANALE M, ANDRIKOU K, PRIANO I, et al. The role of TP53 mutations in EGFR-mutated non-small-cell lung cancer: clinical significance and implications for therapy ［J］. Cancers, 2022, 14(5): 1143.

[22] [22] WILGUCKI M, YEUNG V, HO G, et al. Osimertinib and capmatinib combination therapy to overcome MET Y1003N-mediated resistance in EGFR-mutant NSCLC: a case report ［J］. JTO Clinical and Research Reports, 2022, 3(10): 100396.

[23] [23] FRIEDLAENDER A, SUBBIAH V, RUSSO A, et al. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment ［J］. Nature Reviews Clinical Oncology, 2022, 19(1): 51-69.

[24] [24] CHEN J, FACCHINETTI F, BRAYE F, et al. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients ［J］. Annals of Oncology, 2022, 33(4): 434-444.

[25] [25] HATA A, KATAKAMI N, TAKASE N, et al. Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: a phase II study (ABCD-study) ［J］. Journal of Clinical Oncology, 2022, 40(16_suppl): 9117.